Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06903338 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
A Phase 3 study of Viral Hepatitis, sponsored by Vir Biotechnology.
- Active
- Registry status
- Phase 3
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT06903338: Active Phase 3 study of Viral Hepatitis, sponsored by Vir Biotechnology.
NCT06903338 is a Phase 3 study of Viral Hepatitis that is active but no longer recruiting, run by Vir Biotechnology. The registered enrollment target is 124 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06903338, a Phase 3 study of Viral Hepatitis, is active but no longer recruiting, sponsored by Vir Biotechnology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
Conditions Studied
Interventions
- DRUG Tobevibart
- DRUG Elebsiran
Study Locations (20)
Other
- Investigative Site - Montreal
- Investigative Site - Ottawa
- Investigative Site - Québec
- Investigative Site - Vancouver
- Investigative Site - Tbilisi
California
- Investigative Site - Los Angeles
- Investigative Site - Redwood City
- Investigative Site - San Francisco
New York
- Investigative Site - New York
- Investigative Site - New York
- Investigative Site - New York
Arizona
- Investigative Site - Chandler
Florida
- Investigative Site - DeLand
Illinois
- Investigative Site - Chicago
Maryland
- Investigative Site - Baltimore
New Jersey
- Investigative Site - Hillsborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2025-03-12 |
| Est. Completion | 2031-05 |
| Phase | Phase 3 |
What the registry record for NCT06903338 still lists
NCT06903338 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Viral Hepatitis appearing as the primary indexed condition, and to 2 interventions - of which Tobevibart is the first listed.
NCT06903338 names 20 study sites across 12 states, led by Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT06903338 about?
NCT06903338 is a clinical study titled "A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection". This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
What is the current status of trial NCT06903338?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2025-03-12. Estimated completion is 2031-05.
What conditions does trial NCT06903338 study?
This clinical trial studies the following conditions: Viral Hepatitis.
What interventions are being tested in trial NCT06903338?
The interventions under investigation include: Tobevibart (DRUG), Elebsiran (DRUG).
Who is sponsoring clinical trial NCT06903338?
This trial is sponsored by Vir Biotechnology, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06903338 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Viral Hepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06903338's enrollment target sits among peer trials
124 1611th of 2000 higher than 386 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI